BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tanaka Y, Yoshida K, Tanahashi T, Okumura N, Matsuhashi N, Yamaguchi K. Phase II trial of neoadjuvant chemotherapy with docetaxel, nedaplatin, and S1 for advanced esophageal squamous cell carcinoma. Cancer Sci 2016;107:764-72. [PMID: 27061001 DOI: 10.1111/cas.12943] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
Number Citing Articles
1 Liu Y, Beeraka NM, Liu J, Chen K, Song B, Song Z, Luo J, Liu Y, Zheng A, Cui Y, Wang Y, Jia Z, Song X, Wang X, Wang H, Qi X, Ren J, Wu L, Cai J, Fang X, Wang X, Sinelnikov MY, Nikolenko VN, Greeshma MV, Fan R. Comparative clinical studies of primary chemoradiotherapy versus S-1 and nedaplatin chemotherapy against stage IVb oesophageal squamous cell carcinoma: a multicentre open-label randomised controlled trial. BMJ Open 2022;12:e055273. [PMID: 35470188 DOI: 10.1136/bmjopen-2021-055273] [Reference Citation Analysis]
2 Tsvetkova D, Ivanova S. Application of Approved Cisplatin Derivatives in Combination Therapy against Different Cancer Diseases. Molecules 2022;27:2466. [PMID: 35458666 DOI: 10.3390/molecules27082466] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Kanda M, Shimizu D, Miyata K, Maeda O, Tanaka C, Inokawa Y, Hattori N, Hayashi M, Ando M, Kuwatsuka Y, Murotani K, Nakayama G, Koike M, Ando Y, Ebata T, Kodera Y. Neoadjuvant docetaxel, oxaliplatin plus S-1 for treating clinical stage III squamous cell carcinoma of the esophagus: Study protocol of an open-label phase II trial. Contemp Clin Trials Commun 2021;24:100853. [PMID: 34820548 DOI: 10.1016/j.conctc.2021.100853] [Reference Citation Analysis]
4 Huang B, Shi H, Gong X, Yu J, Xiao C, Zhou B, Liang Z, Li X. Comparison of efficacy and safety between pembrolizumab combined with chemotherapy and simple chemotherapy in neoadjuvant therapy for esophageal squamous cell carcinoma. J Gastrointest Oncol 2021;12:2013-21. [PMID: 34790369 DOI: 10.21037/jgo-21-610] [Reference Citation Analysis]
5 Imai T, Tanaka Y, Sato Y, Mase J, Suetsugu T, Fukada M, Yasufuku I, Iwata Y, Mori R, Imai H, Kato T, Okumura N, Matsuhashi N, Takahashi T, Futamura M, Yoshida K. The Role of Adjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma Patients with Pathological Positive Lymph Nodes After Neoadjuvant Chemotherapy Followed by Esophagectomy: a Single Institute Retrospective Analysis. Indian J Surg Oncol 2021;:1-9. [PMID: 34483594 DOI: 10.1007/s13193-021-01419-0] [Reference Citation Analysis]
6 Yoshida K, Tanaka Y, Imai T, Sato Y, Hatanaka Y, Suetsugu T, Okumura N, Matsuhashi N, Takahashi T, Yamaguchi K. Subtotal stomach in esophageal reconstruction surgery achieves an anastomotic leakage rate of less than 1%. Ann Gastroenterol Surg 2020;4:422-32. [PMID: 32724886 DOI: 10.1002/ags3.12336] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Nishida N, Yamsaki M, Odagiri K, Yamashita K, Tanaka K, Sakai D, Makino T, Takahashi T, Kurokawa Y, Satoh T, Mori M, Doki Y. Combination Therapy With S-1, Oxaliplatin and Leucovorin in Patients With Advanced Esophageal Squamous Cell Carcinoma. In Vivo 2019;33:2249-54. [PMID: 31662564 DOI: 10.21873/invivo.11730] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
8 Qiu X, Li J, Zhou H, Zhang M, Jiang C, Shen Z, Zhu X, Li A, Che Y, Wu T, Wang Z. Concurrent chemoradiotherapy with raltitrexed and nedaplatin regimen for esophageal squamous cell carcinoma. Medicine (Baltimore) 2020;99:e18732. [PMID: 31977864 DOI: 10.1097/MD.0000000000018732] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Zhu H, Ge X, Lu Y, Zuo Y, Qin Q, Sun X, Yang M. Nedaplatin-based chemotherapy regimens combined with concurrent radiotherapy as first-line treatment for stage II-III esophageal squamous cell carcinoma. Oncol Lett 2019;17:594-602. [PMID: 30655806 DOI: 10.3892/ol.2018.9564] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
10 Tanaka Y, Yoshida K, Suetsugu T, Imai T, Matsuhashi N, Yamaguchi K. Recent advancements in esophageal cancer treatment in Japan. Ann Gastroenterol Surg 2018;2:253-65. [PMID: 30003188 DOI: 10.1002/ags3.12174] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 5.5] [Reference Citation Analysis]
11 Sohda M, Kuwano H. Current Status and Future Prospects for Esophageal Cancer Treatment. Ann Thorac Cardiovasc Surg. 2017;23:1-11. [PMID: 28003586 DOI: 10.5761/atcs.ra.16-00162] [Cited by in Crossref: 83] [Cited by in F6Publishing: 88] [Article Influence: 13.8] [Reference Citation Analysis]
12 Tanaka Y, Yoshida K, Tanahashi T, Okumura N, Matsuhashi N, Yamaguchi K. Phase II trial of neoadjuvant chemotherapy with docetaxel, nedaplatin, and S1 for advanced esophageal squamous cell carcinoma. Cancer Sci 2016;107:764-72. [PMID: 27061001 DOI: 10.1111/cas.12943] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]